T BILOGY A C S

Prasugrel versus clopidogrel for patients with unstable angina/non-ST-segment elevation myocardial infarction who are medically managed after angiographic triage — Results from the TRILOGY ACS Trial

Stephen D. Wiviott, MD, Harvey D. White, MB, ChB, DSc, E. Magnus Ohman, MB, ChB, Keith A. A. Fox, MB, ChB, Paul W. Armstrong, MD, Dorairaj Prabhakaran, MD, DM, MSc, Gail Hafley, MS, William E. Boden, MD, Christian Hamm, MD, Peter Clemmensen, MD, DMSc, Jose C. Nicolau, MD, PhD, Alberto Menozzi, MD, PhD, Witold Ruzyllo, MD, Petr Widimsky, MD, DSc, Ali Oto, MD, Jose Leiva-Pons, MD, Gregory Pavlides, MD, Matthew T. Roe, MD, MHS, and Deepak L. Bhatt, MD, MPH

On behalf of the TRILOGY ACS Investigators

www.clinicaltrials.gov Identifier: NCT00699998

A C S Authors and Disclosures*

The TRILOGY ACS Trial was funded by Eli Lilly & Company and Daiichi Sankyo.

Stephen D. Wiviott—grant/research support from Eli Lilly & Company, AstraZeneca,Merck, Eisai; Consulting fees/honoraria from Eli Lilly & Company, Daiichi Sankyo, AstraZeneca, BMS, Sanofi-Aventis, Eisai.

Petr Widimsky—consulting fees/honoraria from Lilly, Ali Raif Ilac Sanayi, Bayer, Daiichi Sankyo, Medtronic, Boehringer Ingelheim, Abbott, AstraZeneca, Sanofi.

Deepak L. Bhatt—honoraria and travel expenses from the Duke Clinical Research Institute; serving as a board member for Medscape Cardiology, Boston VA Research Institute, Society of Chest Pain Centers; grant funding from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi-Aventis, The Medicines Company; payment for developing educational presentations from WebMD; serving on clinical trial steering committees for the Duke Clinical Research Institute; serving as an editor for the American College of Cardiology and chief medical editor for Slack Publications.


Gail Hafley and Witold Ruzyllo --- nothing to report.

*For all other authors, see MT Roe et al, NEJM 2012


A C S Angiography Background

- The proportion of ACS (UA/NSTEMI) patients worldwide who are managed medically without revascularization (PCI or CABG) is 40–60%. This includes 2 distinct sets of patients:
 - triaged to medical therapy after angiography
 - for whom angiography is not performed
- Prasugrel, a thienopyridine P2Y₁₂ inhibitor, improved ischemic outcomes in ACS patients undergoing PCI in the TRITON-TIMI 38 trial, with an increase in major bleeding.

TRILOGY A C S (Age < 75 years, N = 7243)





Roe MT NEJM 2012





*For angiography vs no angiography comparisons — p-values unadjusted, for prasugrel vs clopidogrel - p-value adjusted for clopidogrel stratum

Incidence of Outcomesby Angiography Status(Age < 75 years)</th>









TRILOGY A C S Conclusions

- Substantial differences exist among patients triaged for medical therapy with or without angiography from TRILOGY ACS.
 - Geographically, subjects from North America, Western Europe, and the Mediterranean tended to have angiography pre-randomization
 - Patients with angiography more often were enrolled with NSTEMI, and had prior history or PCI or CABG
- Patients with angiography had lower overall events rates, particularly CV death.

TRILOGY A C S Conclusions

- Overall, in the TRILOGY ACS Trial prasugrel did not reduce cardiovascular events among patients managed medically for ACS.
- When treated with prasugrel compared to clopidogrel, patients triaged to medical therapy following angiography tended to have:
 - lower rates of the combined endpoint of CVD/MI/CVA
 - Lower rates of MI, CVA alone, and recurrent ischemic events
 - higher rates of bleeding.

Though hypothesis generating, these results are consistent with previous trials and suggest when angiography is performed and coronary disease is confirmed, the benefits and risks of intensive antiplatelet therapy exist whether medical therapy or PCI is elected.